Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Acute myocardial infarction (AMI) is myocardial necrosis caused by acute and continuous
ischemia and hypoxia of coronary artery. It can be complicated with arrhythmia, shock or
heart failure, which is often life-threatening. The disease is the most common in Europe and
the United States, where about 1.5 million people suffer from myocardial infarction every
year. China has shown an obvious upward trend in recent years, with at least 500000 new cases
every year and at least 2 million current cases . At present, China has a high incidence rate
of heart failure after myocardial infarction. The incidence of heart failure within 7 days
after myocardial infarction is 19.3%, and the incidence of heart failure from 30 days to 6.7
years after myocardial infarction is 13.1%~37.5%. The incidence of heart failure after
myocardial infarction significantly increases the risk of short-term and long-term death, and
the prognosis is poor. At present, there is a lack of unified guidance and norms for the
diagnosis, treatment and prevention and control strategies of heart failure after myocardial
infarction. Cardiac remodeling is the basic pathological process of heart failure after
myocardial infarction, and it is also one of the main factors affecting the prognosis of
patients. Studies have shown that 30% of AMI have ventricular remodeling 6 months after
percutaneous coronary intervention (PCI), and the risk of ventricular remodeling in anterior
wall myocardial infarction is the highest. According to foreign literature data, the
probability of ventricular remodeling after anterior wall acute myocardial infarction is
about 13%, which is 1.9 times higher than that in other parts.Opening the infarct related
coronary artery early can save the dying myocardium, reduce the infarct myocardial area and
reduce the loss of cardiomyocytes.